Genetic variants in PNPLA3 and HSD17B13 may be one of the targets to be knocked down by RNA interference and antisense oligonucleotide therapies [39,40,108], leading to the prevention of the development to severe liver diseases in patients with MASLD/MASH. Here, PNPLA3 is linked to metabolic dysfunction-associated steatohepatitis.